Download the paper to receive the latest real-world analysis of the 7 practice gaps impacting patients receiving the best treatment from them. In this white paper Diaceutics analysis how the practice gaps have evolved and the barriers which still exist to delivering the promise of precision medicine to every patient.
Building on the globally recognised 2022 study
#TheClinicalPracticeGaps
*Mandatory fields. For details on how we process your personal data, see our Diaceutics Privacy Statement
Now, we’re releasing Part 2, a fresh, data driven analysis looking at how the seven practice gaps have evolved and where patients are still being lost.
Haven’t read the first paper? It’s a must read foundation.
Are we closing the gaps… or widening them?
Pharma, lab and industry leaders all asked us one question more than any other after the first Clinical Practice Gaps Analysis: “Is the 64% number getting better?”
Over the past four years, the precision medicine ecosystem has expanded rapidly - with broader biomarker panels, increased therapeutic options, wider NGS adoption, and more frequent guideline updates.
Our new Clinical Practice Gaps Analysis – Part 2 gives a four year update on the seven gaps identified in the original report downloaded by 31,000+ clinicians, industry leaders, and pharma partners worldwide.
Did the system improve or did the gaps simply shift?
Copyright © 2024, Diaceutics. All rights reserved
The healthcare ecosystem has evolved fast.
But have the factors preventing patients from receiving the right treatment evolved with it?
The Clinical Practice Gaps in Precision Medicine
The new data tells a story that every stakeholder should understand. If you’re shaping strategy, diagnostics, or commercialization plans these insights matter.
Discover:
- How patient loss has shifted across the seven practice gaps
- Where guideline-discordant decisions persist
- What steps we can take today to close the practice gaps
